[Comparison of the Early Efficacy and Serious Adverse Events between CCCG-ALL 2015 and CCLG-ALL 2008 in the Treatment of Pediatric Patients with Acute Lymphoblastic Leukemia].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Zhongguo shi yan xue za zhi she Country of Publication: China NLM ID: 101084424 Publication Model: Print Cited Medium: Print ISSN: 1009-2137 (Print) Linking ISSN: 10092137 NLM ISO Abbreviation: Zhongguo Shi Yan Xue Ye Xue Za Zhi Subsets: MEDLINE
    • Publication Information:
      Original Publication: Beijing : Zhongguo shi yan xue za zhi she,
    • Subject Terms:
      Antineoplastic Combined Chemotherapy Protocols*/therapeutic use ; Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy; Child ; Disease-Free Survival ; Humans ; Neoplasm, Residual/drug therapy ; Neoplasm, Residual/etiology ; Prognosis ; Retrospective Studies ; Treatment Outcome
    • Abstract:
      Objective: To evaluate the early efficacy and serious adverse events (SAE) related to chemotherapy of different protocols in the treatment of pediatric patients with acute lymphoblastic leukemia (ALL), so as to improve the overall survival rate.
      Methods: A comparison of the early efficacy and SAE was performed between pediatric patients treated with Chinese Children Cancer Group-ALL 2015 (CCCG-ALL 2015) protocol from January 2019 to June 2020 and those treated with Chinese Children Leukemia Group-ALL 2008 (CCLG-ALL 2008) protocol from January 2017 to December 2018.
      Results: The remission rate before consolidation chemotherapy between the two groups was not significantly different (P=0.198), but the negative conversion rate of minimal residual disease (MRD) in CCLG-ALL 2008 group was significantly higher than that in CCCG-ALL 2015 group (P=0.000). The incidence of SAE in CCCG-ALL 2015 group was significantly lower than that in CCLG-ALL 2008 group (P=0.021), and the incidence of infection-related SAE was significantly higher in the latter (P=0.001), while the difference of non-infection-related SAE was not statistically significant (P=0.623). In addition, the treatment-related mortality in CCCG-ALL 2015 group was significantly lower than that in CCLG-ALL 2008 group (P=0.003).
      Conclusion: CCCG-ALL 2015 regimen reduces the intensity of chemotherapy, which can significantly decrease the chemotherapy-related SAE (especially infection-related SAE), as well as treatment-related mortality. However, the MRD negative conversion rate is low before consolidation treatment, and the overall long-term efficacy remains to be further observed.
    • Contributed Indexing:
      Keywords: acute lymphoblastic leukemia; children; efficacy; serious adverse event
      Local Abstract: [Publisher, Chinese] CCCG-ALL 2015方案与CCLG-ALL 2008方案治疗儿童急性淋巴细胞白血病的早期疗效及严重不良事件对比. [Publisher, Chinese] 探讨不同方案治疗儿童急性淋巴细胞白血病（ALL）的早期疗效及严重不良事件（SAE），以进一步提高ALL患儿总体生存率. [Publisher, Chinese] 对比2019年1月至2020年6月接受中国儿童肿瘤协作组-ALL 2015方案治疗 （CCCG-ALL 2015方案组）与2017年1月至2018年12月接受中国儿童白血病协作组-ALL 2008方案治疗（CCLG- ALL 2008方案组）患儿的早期疗效和SAE. [Publisher, Chinese] 两组患儿巩固化疗前完全缓解率差异无统计学意义（P=0.198），但微小残留病转阴率CCLG-ALL 2008方案组显著高于CCCG-ALL 2015方案组（P=0.000）。CCCG-ALL 2015方案组SAE发生率显著低于CCLG-ALL 2008方案组（P=0.021），且感染相关SAE发生率后者显著高于前者（P=0.001），而非感染相关SAE差异无统计学意义（P=0.623）。CCCG-ALL 2015方案组治疗相关死亡率显著低于CCLG-ALL 2008方案组（P=0.003）. [Publisher, Chinese] CCCG-ALL 2015方案降低了化疗的强度，能显著降低化疗相关SAE尤其是感染相关SAE的发生率，并降低治疗相关死亡率，但巩固治疗前微小残留病转阴率较低，总体远期疗效仍有待进一步随访观察.
    • Publication Date:
      Date Created: 20220610 Date Completed: 20220613 Latest Revision: 20220613
    • Publication Date:
      20231215
    • Accession Number:
      10.19746/j.cnki.issn.1009-2137.2022.03.010
    • Accession Number:
      35680796